Home Finance specialist Curaleaf International Announces Historic Registration of Exclusive Range of Cannabis Products in...

Curaleaf International Announces Historic Registration of Exclusive Range of Cannabis Products in Malta


Significant momentum with new registration further enhancing European footprint

LONDON, April 29, 2022–(BUSINESS WIRE)–Curaleaf International (the “Company”), part of Curaleaf Holdings (CNSX: CURA), Europe’s largest vertically integrated cannabis company, is pleased to announce it has been granted license of the Company’s range of cannabis medicinal products in extract form, under the name Adven, in Malta.

The product line is manufactured to meet the growing demand for high quality medical cannabis products across Europe and builds on the fact that Curaleaf International is the first company to register a THC cannabis extract Active Pharmaceutical Ingredient ( “API”) in Italy. The products are already being prescribed to a growing number of patients in the UK and Germany.

The range of licensed cannabis medicines includes a variety of different strengths and formulations of THC/CBD in oil form, which will meet a wide range of specialist requirements, all of 100% European origin, from ‘factory to manufacture and EU-GMP certified through the company. vertically integrated company.

Commenting on this landmark recording, Curaleaf International CEO Antonio Costanzo said: “We are very proud of this achievement. Using Curaleaf International’s regulatory expertise in pharmaceuticals, we have obtained registration for a full range of medicines to support the demands of doctors, pharmacists and patients in high quality cannabis products.We believe this will usher in a new era of opportunities for licensed cannabis medicinal products in the Maltese market.This news, in addition to our recent registration in Italy, is a very strong boost. promising for Curaleaf International as we continue to see growing demand for our products in the growing European market.”

Commenting on Curaleaf International’s broader research strategy, Barbara Pacchetti, Scientific Director, said: Curaleaf International is committed to advancing the industry’s understanding of the medical potential of cannabis through licensed cannabis-based medicines. We foresee a new era of placing cannabis-based medicine in disease treatment protocols alongside conventional medications. Our pioneering scientific and clinical research programs are designed to provide more clinical data to support the growing medical cannabis market. Our goal is to continue to generate evidence regarding the potential therapeutic benefits of medical cannabis for patients and clinicians. »

About Curaleaf International

Curaleaf International (formerly EMMAC Life Sciences Group) is the largest vertically integrated cannabis company in Europe, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network across Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021.

For more information about Curaleaf International, please visit: https://www.curaleafinternational.com/.


All statements, other than statements of historical facts, contained in this press release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, future plans and objectives. of Curaleaf International. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the short term.

Actual results and future events could differ materially from those anticipated in these statements. These written and oral forward-looking statements and all subsequent forward-looking statements are based on management’s estimates and opinions as of the dates they are made and are expressly qualified in their entirety by this notice. Curaleaf International undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions change.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220428006324/en/


Media inquiries:
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz
Tel: +44 (0) 20 7466 5000
[email protected]